SCHEMBL1380809

SCHEMBL1380809

CC1(C)NC(=O)N(CCCC[C@@H](NS(=O)(=O)c2ccc(-c3ccc(Cl)cc3)cc2)C(=O)O)C1=O

nearest known ligand 0.50

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 12/20 0.50
MMP9 P14780 11/20 0.50
ADAMTS5 Q9UNA0 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.47
ALDH1A1 P00352 1/20 0.47
LMNA P02545 1/20 0.47
GAA P10253 1/20 0.47
HTT P42858 1/20 0.47
MAPK1 P28482 1/20 0.45
MMP13 P45452 2/20 0.45
MMP8 P22894 1/20 0.45
ADAMTS4 O75173 1/20 0.45
MMP1 P03956 1/20 0.45
MMP3 P08254 1/20 0.45
MMP7 P09237 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1380810 1.00 MMP2 (0.50) MMP2MMP9ADAMTS5SMN1; SMN2ALDH1A1
SCHEMBL7952570 0.91 BMP1 (0.47) MMP2MMP9ADAMTS5SMN1; SMN2ALDH1A1
SCHEMBL7952568 0.91 BMP1 (0.47) MMP2MMP9ADAMTS5SMN1; SMN2ALDH1A1
SCHEMBL7954592 0.88 MMP2 (0.51) MMP2MMP9ADAMTS5MMP13MMP8
SCHEMBL7954589 0.88 MMP2 (0.51) MMP2MMP9ADAMTS5MMP13MMP8
SCHEMBL1379461 0.85 MMP2 (0.52) MMP2MMP9ADAMTS5MMP13MMP8
SCHEMBL1376076 0.81 MMP2 (0.53) MMP2MMP9ADAMTS5MMP13MMP8
SCHEMBL5033356 0.77 MMP2 (0.69) MMP2MMP9ADAMTS5MMP13MMP8
SCHEMBL1380533 0.77 MMP2 (0.54) MMP2MMP9ADAMTS5MMP13MMP8
SCHEMBL7959937 0.77 MMP2 (0.69) MMP2MMP9ADAMTS5MMP13MMP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4750272-B2 2011-08-17 JP claimed
EP-1918278-A1 Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases Novartis AG (CH) 2008-05-07 EP claimed
US-6277987-B1 FOR INHIBITING MATRIX-DEGRADING METALLOPROTEINASES IN MAMMALS NOVARTIS AG (CH) 2001-08-21 US claimed
EP-1053226-A1 SULFONYLAMINO DERIVATIVES WHICH INHIBIT MATRIX-DEGRADING METALLOPROTEINASES Novartis AG (CH) 2000-11-22 EP claimed
WO-1999042443-A1 SULFONYLAMINO DERIVATIVES WHICH INHIBIT MATRIX-DEGRADING METALLOPROTEINASES NOVARTIS AG (CH) 1999-08-26 WO claimed
EP-1918278-A1 Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases Novartis AG (CH) 2008-05-07 EP disclosed
US-6410580-B1 ANTIINFLAMMATORY AGENTS, RHEUMATIC DISEASES NOVARTIS AG (CH) 2002-06-25 US disclosed
EP-1053226-A1 SULFONYLAMINO DERIVATIVES WHICH INHIBIT MATRIX-DEGRADING METALLOPROTEINASES Novartis AG (CH) 2000-11-22 EP disclosed
WO-1999042443-A1 SULFONYLAMINO DERIVATIVES WHICH INHIBIT MATRIX-DEGRADING METALLOPROTEINASES NOVARTIS AG (CH) 1999-08-26 WO disclosed